{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T14:16:55Z","timestamp":1760710615923,"version":"3.37.3"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,6,6]],"date-time":"2021-06-06T00:00:00Z","timestamp":1622937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,6]],"date-time":"2021-06-06T00:00:00Z","timestamp":1622937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A 77-year-old man with past medical history of granulomatosis with polyangiitis (GPA) on rituximab and prednisone, presented to the hospital with worsening cough and shortness of breath. He had tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by nasal swab polymerase chain reaction (PCR) while asymptomatic, 6\u00a0weeks earlier. He started with cough and shortness of breath 2\u00a0weeks after his initial positive test. After developing symptoms, he tested negative twice by nasal swab PCR, but the PCR of his bronchioloalveolar lavage was positive for SARS-CoV-2. He did not develop antibodies against coronavirus. Prednisone 15\u00a0mg daily was continued, and he received remdesivir, and convalescent plasma with quick recovery. We reviewed the literature to search for similar cases. Our case suggests that SARS-CoV-2 infection in patients on rituximab may have an atypical presentation and the diagnosis may be delayed due to negative PCR testing in the nasal swab. Patients may benefit from treatment with convalescent plasma.<\/jats:p>","DOI":"10.1007\/s00296-021-04905-4","type":"journal-article","created":{"date-parts":[[2021,6,6]],"date-time":"2021-06-06T11:02:21Z","timestamp":1622977341000},"page":"1509-1514","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["COVID-19 pneumonia in a patient with granulomatosis with polyangiitis on rituximab: case-based review"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6255-5306","authenticated-orcid":false,"given":"Alicia","family":"Rodriguez-Pla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6391-0349","authenticated-orcid":false,"given":"Holenarasipur R.","family":"Vikram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanood","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9013-6221","authenticated-orcid":false,"given":"Lewis J.","family":"Wesselius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,6]]},"reference":[{"key":"4905_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219279[publishedOnlineFirst:2020\/12\/02]","author":"N Serling-Boyd","year":"2020","unstructured":"Serling-Boyd N, D\u2019Silva KM, Hsu TY, Wallwork R, Fu X, Gravallese EM et al (2020) Coronavirus disease 2019 outcomes among patients with rheumatic diseases 6 months into the pandemic. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2020-219279[publishedOnlineFirst:2020\/12\/02]","journal-title":"Ann Rheum Dis"},{"key":"4905_CR2","doi-asserted-by":"publisher","first-page":"102442","DOI":"10.1016\/j.jaut.2020.102442","volume":"109","author":"A Ceribelli","year":"2020","unstructured":"Ceribelli A, Motta F, De Santis M, Ansari AA, Ridgway WM, Gershwin ME et al (2020) Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy. J Autoimmun 109:102442. https:\/\/doi.org\/10.1016\/j.jaut.2020.102442","journal-title":"J Autoimmun"},{"issue":"10","key":"4905_CR3","doi-asserted-by":"publisher","first-page":"e589","DOI":"10.1016\/S2665-9913(20)30270-8","volume":"2","author":"P Mehta","year":"2020","unstructured":"Mehta P, Porter JC, Chambers RC, Isenberg DA, Reddy V (2020) B-cell depletion with rituximab in the COVID-19 pandemic: where do we stand? Lancet Rheumatol 2(10):e589\u2013e590. https:\/\/doi.org\/10.1016\/S2665-9913(20)30270-8","journal-title":"Lancet Rheumatol"},{"issue":"3","key":"4905_CR4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJMoa2029849","volume":"384","author":"P Chen","year":"2021","unstructured":"Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J et al (2021) SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med 384(3):229\u2013237","journal-title":"N Engl J Med"},{"key":"4905_CR5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031893","author":"MJ Joyner","year":"2021","unstructured":"Joyner MJ, Carter RE, Senefeld JW, Klassen SA, Mills JR, Johnson PW et al (2021) Convalescent plasma antibody levels and the risk of death from Covid-19. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2031893","journal-title":"N Engl J Med"},{"issue":"12","key":"4905_CR6","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1136\/annrheumdis-2015-207841","volume":"74","author":"KL Winthrop","year":"2015","unstructured":"Winthrop KL, Novosad SA, Baddley JW, Calabrese L, Chiller T, Polgreen P et al (2015) Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance. Ann Rheum Dis 74(12):2107\u20132116. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207841","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"4905_CR7","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1177\/0961203318792352","volume":"27","author":"SC Yang","year":"2018","unstructured":"Yang SC, Lai YY, Huang MC, Tsai CS, Wang JL (2018) Corticosteroid dose and the risk of opportunistic infection in a national systemic lupus erythematosus cohort. Lupus 27(11):1819\u20131827. https:\/\/doi.org\/10.1177\/0961203318792352","journal-title":"Lupus"},{"issue":"5","key":"4905_CR8","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1097\/00002281-200309000-00002","volume":"15","author":"I Kang","year":"2003","unstructured":"Kang I, Park SH (2003) Infectious complications in SLE after immunosuppressive therapies. Curr Opin Rheumatol 15(5):528\u2013534. https:\/\/doi.org\/10.1097\/00002281-200309000-00002","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"4905_CR9","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00281-017-0629-x","volume":"39","author":"R Channappanavar","year":"2017","unstructured":"Channappanavar R, Perlman S (2017) Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol 39(5):529\u2013539. https:\/\/doi.org\/10.1007\/s00281-017-0629-x","journal-title":"Semin Immunopathol"},{"issue":"10229","key":"4905_CR10","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","volume":"395","author":"P Mehta","year":"2020","unstructured":"Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ et al (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395(10229):1033\u20131034. https:\/\/doi.org\/10.1016\/S0140-6736(20)30628-0","journal-title":"Lancet"},{"issue":"1","key":"4905_CR11","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1056\/NEJMc2009567","volume":"383","author":"R Haberman","year":"2020","unstructured":"Haberman R, Axelrad J, Chen A, Castillo R, Yan D, Izmirly P et al (2020) Covid-19 in immune-mediated inflammatory diseases\u2014case series from New York. N Engl J Med 383(1):85\u201388. https:\/\/doi.org\/10.1056\/NEJMc2009567","journal-title":"N Engl J Med"},{"issue":"5","key":"4905_CR12","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1136\/annrheumdis-2020-217424","volume":"79","author":"S Monti","year":"2020","unstructured":"Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C (2020) Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis 79(5):667\u2013668. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217424","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"4905_CR13","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","volume":"47","author":"GJ Weiner","year":"2010","unstructured":"Weiner GJ (2010) Rituximab: mechanism of action. Semin Hematol 47(2):115\u2013123. https:\/\/doi.org\/10.1053\/j.seminhematol.2010.01.011","journal-title":"Semin Hematol"},{"issue":"7","key":"4905_CR14","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1136\/annrheumdis-2020-217871","volume":"79","author":"M Gianfrancesco","year":"2020","unstructured":"Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L et al (2020) Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 79(7):859\u2013866. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217871","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4905_CR15","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40620-020-00881-3","volume":"34","author":"S Kant","year":"2021","unstructured":"Kant S, Morris A, Ravi S, Floyd L, Gapud E, Antichos B et al (2021) The impact of COVID-19 pandemic on patients with ANCA associated vasculitis. J Nephrol 34(1):185\u2013190. https:\/\/doi.org\/10.1007\/s40620-020-00881-3","journal-title":"J Nephrol"},{"key":"4905_CR16","doi-asserted-by":"publisher","first-page":"651715","DOI":"10.3389\/fimmu.2021.651715","volume":"12","author":"SN Esatoglu","year":"2021","unstructured":"Esatoglu SN, Tascilar K, Babaoglu H, Bes C, Yurttas B, Akar S et al (2021) COVID-19 among patients with inflammatory rheumatic diseases. Front Immunol 12:651715. https:\/\/doi.org\/10.3389\/fimmu.2021.651715","journal-title":"Front Immunol"},{"key":"4905_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.02086","author":"MA Schramm","year":"2020","unstructured":"Schramm MA, Venhoff N, Wagner D, Thiel J, Huzly D, Craig-Mueller N et al (2020) COVID-19 in a severely immunosuppressed patient with life-threatening eosinophilic granulomatosis with polyangiitis. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2020.02086","journal-title":"Front Immunol"},{"issue":"1","key":"4905_CR18","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1136\/annrheumdis-2020-217549","volume":"80","author":"P Guilpain","year":"2021","unstructured":"Guilpain P, Le Bihan C, Foulongne V, Taourel P, Pansu N, Maria ATJ et al (2021) Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia. Ann Rheum Dis 80(1):e10. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217549","journal-title":"Ann Rheum Dis"},{"key":"4905_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218246","author":"S Suarez-Diaz","year":"2020","unstructured":"Suarez-Diaz S, Moran-Castano C, Coto-Hernandez R, Mozo-Avellaneda L, Suarez-Cuervo C, Caminal-Montero L (2020) Mild COVID-19 in ANCA-associated vasculitis treated with rituximab. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218246","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"4905_CR20","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1002\/art.41380","volume":"72","author":"B Fallet","year":"2020","unstructured":"Fallet B, Kyburz D, Walker UA (2020) Mild course of COVID-19 and spontaneous virus clearance in a patient with depleted peripheral blood B cells due to rituximab treatment. Arthritis Rheumatol 72(9):1581\u20131582. https:\/\/doi.org\/10.1002\/art.41380","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"4905_CR21","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1136\/annrheumdis-2020-217948","volume":"79","author":"C Sanchez-Piedra","year":"2020","unstructured":"Sanchez-Piedra C, Diaz-Torne C, Manero J, Pego-Reigosa JM, Rua-Figueroa I, Gonzalez-Gay MA et al (2020) Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies. Ann Rheum Dis 79(7):988\u2013990. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217948","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"4905_CR22","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1136\/annrheumdis-2020-218054","volume":"79","author":"L Nuno","year":"2020","unstructured":"Nuno L, Novella Navarro M, Bonilla G, Franco-Gomez K, Aguado P, Peiteado D et al (2020) Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases. Ann Rheum Dis 79(12):1659\u20131661. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218054","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"4905_CR23","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1007\/s00296-020-04699-x","volume":"40","author":"J Loarce-Martos","year":"2020","unstructured":"Loarce-Martos J, Garcia-Fernandez A, Lopez-Gutierrez F, Garcia-Garcia V, Calvo-Sanz L, Del Bosque-Granero I et al (2020) High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study. Rheumatol Int 40(12):2015\u20132021. https:\/\/doi.org\/10.1007\/s00296-020-04699-x","journal-title":"Rheumatol Int"},{"key":"4905_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001332","author":"R Hasseli","year":"2020","unstructured":"Hasseli R, Mueller-Ladner U, Schmeiser T, Hoyer BF, Krause A, Lorenz HM et al (2020) National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2020-001332","journal-title":"RMD Open"},{"key":"4905_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00059-X","author":"J Avouac","year":"2021","unstructured":"Avouac J, Drumez E, Hachulla E, Seror R, Georgin-Lavialle S, El Mahou S et al (2021) COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. Lancet Rheumatol. https:\/\/doi.org\/10.1016\/S2665-9913(21)00059-X","journal-title":"Lancet Rheumatol"},{"key":"4905_CR26","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.200755","author":"J Bachiller-Corral","year":"2021","unstructured":"Bachiller-Corral J, Boteanu A, Garcia-Villanueva MJ, de la Puente C, Revenga M, Diaz-Miguel MC et al (2021) Risk of severe coronavirus infection (COVID-19) in patients with inflammatory rheumatic diseases. J Rheumatol. https:\/\/doi.org\/10.3899\/jrheum.200755","journal-title":"J Rheumatol"},{"issue":"8","key":"4905_CR27","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.3899\/jrheum.200507","volume":"47","author":"EG Favalli","year":"2020","unstructured":"Favalli EG, Agape E, Caporali R (2020) Incidence and clinical course of COVID-19 in patients with connective tissue diseases: a descriptive observational analysis. J Rheumatol 47(8):1296. https:\/\/doi.org\/10.3899\/jrheum.200507","journal-title":"J Rheumatol"},{"key":"4905_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218075","author":"H Schulze-Koops","year":"2020","unstructured":"Schulze-Koops H, Krueger K, Vallbracht I, Hasseli R, Skapenko A (2020) Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218075","journal-title":"Ann Rheum Dis"},{"key":"4905_CR29","doi-asserted-by":"publisher","unstructured":"Benucci M, Quartuccio L, Li Gobbi F, Damiani A, Grossi V, Infantino M, et al (2020) Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koops et al. Ann Rheum Dis https:\/\/doi.org\/10.1136\/annrheumdis-2020-218590","DOI":"10.1136\/annrheumdis-2020-218590"},{"key":"4905_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217864","author":"J Avouac","year":"2020","unstructured":"Avouac J, Airo P, Carlier N, Matucci-Cerinic M, Allanore Y (2020) Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217864","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"4905_CR31","first-page":"001922","volume":"7","author":"P Daniel","year":"2020","unstructured":"Daniel P, Raad M, Waked R, Choucair J, Riachy M, Haddad F (2020) COVID-19 in a patient treated for granulomatosis with polyangiitis: persistent viral shedding with no cytokine storm. Eur J Case Rep Intern Med 7(10):001922","journal-title":"Eur J Case Rep Intern Med"},{"key":"4905_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218491","author":"S Hakroush","year":"2020","unstructured":"Hakroush S, Franz J, Larsen J, Korsten P, Winkler MS, Tampe B (2020) Repeated false-negative tests delayed diagnosis of COVID-19 in a case with granulomatosis with polyangiitis under maintenance therapy with rituximab and concomitant influenza pneumonia. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218491","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"4905_CR33","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.semarthrit.2020.06.013","volume":"50","author":"J Leipe","year":"2020","unstructured":"Leipe J, Wilke EL, Ebert MP, Teufel A, Reindl W (2020) Long, relapsing, and atypical symptomatic course of COVID-19 in a B-cell-depleted patient after rituximab. Semin Arthritis Rheu 50(5):1087\u20131088. https:\/\/doi.org\/10.1016\/j.semarthrit.2020.06.013","journal-title":"Semin Arthritis Rheu"},{"key":"4905_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220088","author":"MA Friedman","year":"2021","unstructured":"Friedman MA, Winthrop KL (2021) Second COVID-19 infection in a patient with granulomatosis with polyangiitis on rituximab. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220088","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-021-04905-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-021-04905-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-021-04905-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T10:07:43Z","timestamp":1625047663000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-021-04905-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,6]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["4905"],"URL":"https:\/\/doi.org\/10.1007\/s00296-021-04905-4","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"type":"print","value":"0172-8172"},{"type":"electronic","value":"1437-160X"}],"subject":[],"published":{"date-parts":[[2021,6,6]]},"assertion":[{"value":"2 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no known competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The patient provided signed consent for the publication of this case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}